A lthough LDL cholesterol is the main target in the treatment of diabetic dyslipidemia, it does not fully account for the cardiovascular risk associated with diabetes, neither alone nor in combination with triglycerides and HDL cholesterol. On the other hand, diabetic dyslipidemia also includes an overall increase in atherogenic particles identifiable, by measuring apolipoprotein B (apoB), and a predominance of small, dense LDL particles (phenotype B). The latter, although associated with increased cardiovascular risk, is not routinely assessed because its measurement is not available to most clinical laboratories. Therefore, easily measurable predictors of LDL size, such as triglycerides or LDL cholesterol/apoB and triglyceride-to-HDL cholesterol ratios, have been proposed, with the latter being suggested as the best surrogate (1,2,3). However, no study has been conducted that compares all of these predictors.
The aim of the present study is to evaluate the triglyceride-to-HDL cholesterol ratio, non-HDL cholesterol, and apoB to predict LDL phenotype and to assess them in the risk classification of patients with type 2 diabetes. High non-HDL cholesterol was defined by the equivalent to an LDL cholesterol Ͼ 3.36 mmol/l, when pharmacological intervention is recommended, i.e., non-HDL cholesterol Ͼ4.13 mmol/l (4). The triglyceride-to-HDL cholesterol ratio was expressed in mmol/l over mmol/l. Previously described cutoff points were used (1, 2, 6) , as well as that calculated from the regression equation obtained from the samples included in the present study: triglyceride-to-HDL cholesterol ratio ϭ 42.122 Ϫ 1.576 ϫ LDL size (R ϭ 0.625) for an LDL size of 25.5 nm. ApoB was measured by an immunoturbidimetric method (Tina-quant, Roche Diagnostics) calibrated against the World Health Organization/International Federation of Clinical Chemistry reference standard SP3-07. Its cutoff point (0.97 g/l) was defined as the equivalent to an LDL cholesterol of 3.36 mmol/l (7) in a previously described nondiabetic normolipidemic control group (8) . LDL size was determined by polyacrylamide gradient (2-16%) gel electrophoresis (3), and LDL phenotype B was defined by a predominant LDL diameter Ͻ25.5 nm.
RESEARCH DESIGN AND METHODS
Patients were classified according to their triglyceride and apoB concentrations as well as according to their triglycerides, triglyceride-to-HDL cholesterol ratio, and their non-HDL cholesterol.
Statistical analysis was performed using the SPSS 10.0 statistical package for Windows (SPSS, Chicago, IL). Results are expressed as means Ϯ SD (Gaussian distribution), median and ranges (nonGaussian distribution), or as percentages. P a t h o p h y s i o l o g y / C o m p l i c a t i o n s 
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ously proposed cutoff points for triglycerides-to-HDL cholesterol, the concordance with their classification into LDL phenotypes A and B was fair ( ϭ 0.390 for a cutoff point of 0.9) to moderate ( ϭ 0.478 for a cutoff point of 1.33 and ϭ 0.545 for a cutoff point of 1.64). When using the regression equation triglycerides/HDL cholesterol ϭ 42.122 Ϫ 1.576 ϫ LDL size (R ϭ 0.625), for an LDL size of 25.5 nm, a triglyceride/HDL cholesterol cutoff point of 1.93 was obtained. When this cutoff point was used, the concordance of the patients' classification with LDL phenotype was also moderate, though slightly better than with the other cutoff points ( ϭ 0.554). It showed a sensitivity of 60% and a specificity of 92% to predict LDL phenotype B. We used 1.93 as the cutoff point to classify the patients (normal-high triglyceride-to-HDL cholesterol ratio) and compare their distribution with when the classification was performed using apoB and triglycerides (Fig. 1) . Using these cutoff points, the concordance between hyperapoB and the hypertriglyceride-to-HDL cholesterol ratio was poor ( ϭ 0.175), whereas the concordance between hyperapoB and hyper-non-HDL cholesterol was moderate ( ϭ 0.522). Results were similar when cutoff points equivalent to LDL cholesterol of 2.59 mmol/l were used for non-HDL cholesterol and apoB, as well as when men and women were analyzed separately (data not shown).
CONCLUSIONS -T h e p r e s e n t study shows that the triglyceride-to-HDL cholesterol ratio is not superior to non-HDL cholesterol in classifying patients with type 2 diabetes into dyslipidemic phenotypes. The triglyceride-to-HDL cholesterol ratio is cheap and easy to calculate and is a good predictor of LDL size. However, it does not identify most of the patients with hyperapoB, has a high biological variability that is inherent to triglycerides (10) , as reflected by the wide range of recommended cutoff points, and its determination should be made in the fasting state. On the other hand, non-HDL cholesterol is as cheap and easy to measure as the triglyceride-to-HDL cholesterol ratio, with the additional advantage that its biologic variability is much lower and fasting samples are not needed. ApoB reflects the total number of atherogenic particles and is superior to non-HDL cholesterol both as a cardiovascular risk predictor and as a predictor of the risk reduction following treatment of dyslipidemia (11) . Its determination can also be made in the nonfasting state (12) , its biological variability is lower than for other lipidic components, and the introduction of an international standard has made results from different labs comparable (13) .
We have previously shown that in hypertriglyceridemic patients, apoB and non-HDL cholesterol are equivalent in classifying them into dyslipidemic phenotypes (14) . This is also true for the triglyceride-to-HDL cholesterol ratio. In normotriglyceridemic subjects, however, non-HDL cholesterol identifies around half of the individuals with hyperapoB (14) , whereas the triglyceride-to-HDL cholesterol ratio identifies Ͻ10% (Fig. 1) .
Therefore, based on current and previous results and the cost-effectiveness of the different components, a strategy consisting of the estimation of non-HDL cholesterol (as a surrogate of apoB) in all of the subjects and the measurement of apoB itself in the normotriglyceridemic subjects with normal non-HDL cholesterol is proposed for dyslipidemic risk classification of patients with type 2 diabetes. The triglyceride-to-HDL cholesterol ratio does not add useful information to the previously mentioned strategy.
